Astellas expects to complete the integration of its US acquisition OSI Pharmaceuticals by the end of June next year, by which time a number of restructuring moves associated with the transaction will have taken place.
The Japanese firm paid around $4 billion for OSI when it closed a tender offer in June, after an occasionally...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?